摘要
目的：探讨特异性免疫治疗（SIT）对儿童哮喘的治疗效果和安全性。方法：对53例尘螨过敏的哮喘患儿采用尘螨标准化变应原进行SIT，通过观察不同时期激素吸入量、肺功能变化和哮喘症状评分确定SIT的效果，分析其不良反应及安全性。结果：于治疗37周开始SIT组激素吸入量较对照组明显降低（t=2．80～5．17，P〈0．01）；治疗51周开始SIT组PEF较对照组明显提高（t=2．07—3．59，P〈0．05），而FEV1两组比较差异无统计学意义（P〉0．05）；治疗第二年，SIT组临床症状评分明显提高（t=4．59～7．36，P〈0．01）；所有患儿无严重不良事件发生。结论：采用尘螨SIT，可明显减少激素吸入剂量。改善肺功能，提高临床症状评分，安全可靠。
Objective：To investigate the effectiveness and safety of standardized dust mite allergen specific immunotherapy in children with asthma. Methods： 53 cases were determined dust mite allergens in children with the use of dust mite allergen standardization to the specific immunotherapy. Then we observed the clinical effects, including different amount of inhaled steroid, the changes in lung function, asthma symptom score and the security in the process of injection. Results：The inhaled steroid dose reduced gradually in children with asthma, and after 37 weeks the inhaled steroid dose of SIT group was lower than that of the control group （t =2. 80-5. 17, P 〈0.01 ）, lung function gradually improved, 51 weeks after the treatment, the PEF （forced expiratory peak flow） of SIT group was higher than that of the control group （t = 2. 07 - 3. 59, P 〈 0.05 ）. and FEV1 between the two groups had no significant difference （P 〉 0.05 ）, The asthma symptom score of SIT group obviously increased the next year （ t = 4. 59 - 7. 36, P 〈 0.01 ） and no serious adverse reaction was observed. Conclusions： The dust mite allergens standardization of SIT can significantly reduce the dose of inhaled steroid, improve lung function, improve clinical symptom score and is secure.
出处
《儿科药学杂志》
CAS
2008年第5期7-10,共4页
Journal of Pediatric Pharmacy
关键词
儿童
哮喘
特异性免疫治疗
标准化变应原
肺功能
Asthma
children
Specific immunotherapy
Standardization of the allergen
Lung function
